GR3036393T3 - ENANTIOMERICALLY PURE -g(b)-D-DIOXOLANE-NUCLEOSIDES. - Google Patents
ENANTIOMERICALLY PURE -g(b)-D-DIOXOLANE-NUCLEOSIDES.Info
- Publication number
- GR3036393T3 GR3036393T3 GR20010401249T GR20010401249T GR3036393T3 GR 3036393 T3 GR3036393 T3 GR 3036393T3 GR 20010401249 T GR20010401249 T GR 20010401249T GR 20010401249 T GR20010401249 T GR 20010401249T GR 3036393 T3 GR3036393 T3 GR 3036393T3
- Authority
- GR
- Greece
- Prior art keywords
- enantiomerically pure
- nucleosides
- dioxolane
- image
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/935,515 US5925643A (en) | 1990-12-05 | 1992-08-25 | Enantiomerically pure β-D-dioxolane-nucleosides |
PCT/US1993/008044 WO1994004154A1 (en) | 1992-08-25 | 1993-08-25 | ENANTIOMERICALLY PURE β-D-DIOXOLANE-NUCLEOSIDES |
Publications (1)
Publication Number | Publication Date |
---|---|
GR3036393T3 true GR3036393T3 (en) | 2001-11-30 |
Family
ID=25467279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR20010401249T GR3036393T3 (en) | 1992-08-25 | 2001-08-14 | ENANTIOMERICALLY PURE -g(b)-D-DIOXOLANE-NUCLEOSIDES. |
Country Status (12)
Country | Link |
---|---|
US (2) | US5925643A (el) |
EP (2) | EP1081148B1 (el) |
JP (3) | JP3519736B2 (el) |
AT (2) | ATE498624T1 (el) |
AU (1) | AU670637C (el) |
CA (1) | CA2143107C (el) |
DE (2) | DE69330274T2 (el) |
DK (1) | DK0656778T3 (el) |
ES (1) | ES2157929T3 (el) |
GR (1) | GR3036393T3 (el) |
PT (1) | PT656778E (el) |
WO (1) | WO1994004154A1 (el) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6903224B2 (en) | 1988-04-11 | 2005-06-07 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes |
US6350753B1 (en) | 1988-04-11 | 2002-02-26 | Biochem Pharma Inc. | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
US5827727A (en) | 1990-02-01 | 1998-10-27 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5914331A (en) * | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
US20020120130A1 (en) | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
DE69636734T2 (de) | 1995-06-07 | 2007-10-18 | Emory University | Nucleoside mit anti-hepatitis b virus wirksamkeit |
US5792773A (en) * | 1996-11-15 | 1998-08-11 | Yale University | L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection |
US6022876A (en) * | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
ATE267198T1 (de) * | 1997-03-19 | 2004-06-15 | Univ Emory | Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden |
DE19739827B4 (de) * | 1997-09-11 | 2007-05-10 | Robert Bosch Gmbh | Verfahren und Vorrichtung zur Steuerung einer Betriebsgröße eines Kraftfahrzeugs |
CN1666742A (zh) | 1998-11-02 | 2005-09-14 | 三角药物公司 | 对乙型肝炎病毒的联合治疗 |
CA2355712C (en) | 1998-12-23 | 2009-03-17 | Shire Biochem Inc. | Antiviral nucleoside analogues |
US6511983B1 (en) | 1999-03-01 | 2003-01-28 | Biochem Pharma Inc. | Pharmaceutical combination of antiviral agents |
US6653318B1 (en) | 1999-07-21 | 2003-11-25 | Yale University | 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
WO2002031176A1 (fr) * | 2000-10-12 | 2002-04-18 | Mitsui Chemicals, Inc. | Procédé permettant la production de nucléosides |
CN102911166B (zh) | 2001-03-01 | 2016-08-17 | 基利得科学公司 | 顺-ftc的多晶型物及其它晶型 |
ATE496054T1 (de) | 2002-08-06 | 2011-02-15 | Pharmasset Inc | Verfahren zur herstellung von 1,3-dioxolan- nucleosiden |
AU2004224191A1 (en) | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
CN1898569A (zh) | 2003-10-24 | 2007-01-17 | 伊缪因艾德有限公司 | 治疗方法 |
WO2005074654A2 (en) | 2004-02-03 | 2005-08-18 | Emory University | Methods to manufacture 1,3-dioxolane nucleosides |
US7446234B2 (en) * | 2005-09-27 | 2008-11-04 | Council Of Scientific And Industrial Research | Bisphenol compound and process for preparation thereof |
KR20080056220A (ko) | 2005-10-19 | 2008-06-20 | 에프. 호프만-라 로슈 아게 | 페닐-아세트아마이드 nnrt 저해제 |
PT2057125E (pt) | 2006-08-16 | 2011-05-31 | Hoffmann La Roche | Inibidores n?o nucle?sidos de transcriptase inversa |
ES2550152T3 (es) | 2006-12-13 | 2015-11-04 | F. Hoffmann-La Roche Ag | Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa |
WO2008145562A1 (en) | 2007-05-30 | 2008-12-04 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
WO2009080534A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
EP2376088B1 (en) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | 6-O-Substituted-2-amino-purine nucleoside phosphoramidates |
ES2548508T3 (es) | 2009-05-27 | 2015-10-19 | Biotempus Limited | Métodos de tratamiento de enfermedades |
WO2011077100A1 (en) | 2009-12-24 | 2011-06-30 | Cipla Limited | Antiretroviral composition |
JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4000137A (en) * | 1975-06-10 | 1976-12-28 | American Home Products Corporation | Antitumor derivatives of periodate-oxidized nucleosides |
JPS5668674A (en) * | 1979-11-08 | 1981-06-09 | Shionogi & Co Ltd | 5-fluorouracil derivative |
EP0206497B1 (en) * | 1985-05-15 | 1994-07-20 | The Wellcome Foundation Limited | Therapeutic nucleosides and their preparation |
US4879277A (en) * | 1985-08-26 | 1989-11-07 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral compositions and methods |
WO1987001284A1 (en) * | 1985-08-26 | 1987-03-12 | United States Of America, Represented By The Unite | Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine |
US4916122A (en) * | 1987-01-28 | 1990-04-10 | University Of Georgia Research Foundation, Inc. | 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition |
US4963533A (en) * | 1986-10-24 | 1990-10-16 | Stichting Rega Vzw (Rega) | Therapeutic application of dideoxycytidinene |
US5011774A (en) * | 1987-07-17 | 1991-04-30 | Bristol-Myers Squibb Co. | Dideoxyinosine by enzymatic deamination of dideoxyadenosine |
US4880784A (en) * | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
NZ228645A (en) * | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5041449A (en) * | 1988-04-11 | 1991-08-20 | Iaf Biochem International, Inc. | 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections |
US5270315A (en) * | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
US5122517A (en) * | 1988-06-10 | 1992-06-16 | Regents Of The University Of Minnesota | Antiviral combination comprising nucleoside analogs |
AU618436B2 (en) * | 1988-12-19 | 1991-12-19 | Wellcome Foundation Limited, The | Antiviral cytosine and guanine derivatives |
NZ233197A (en) * | 1989-04-13 | 1991-11-26 | Richard Thomas Walker | Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions |
US5059690A (en) * | 1990-03-01 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Purinyl tetrahydrofurans |
US5071983A (en) * | 1989-10-06 | 1991-12-10 | Burroughs Wellcome Co. | Therapeutic nucleosides |
IE904378A1 (en) * | 1989-12-20 | 1991-07-03 | Abbott Lab | Analogs of oxetanyl purines and pyrimidines |
US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
US5248776A (en) * | 1990-12-05 | 1993-09-28 | University Of Georgia Research Foundation, Inc. | Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides |
AU9125991A (en) * | 1990-12-05 | 1992-07-08 | University Of Georgia Research Foundation, Inc., The | Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides |
US5179104A (en) * | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
DE69120830T2 (de) | 1990-12-14 | 1997-02-27 | Henkel Corp | Im wesentlichen phosphatfreies, schwach saueres reinigungsmittel für kunststoffartikel |
IL100502A (en) * | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
GB9104740D0 (en) * | 1991-03-06 | 1991-04-17 | Wellcome Found | Antiviral nucleoside combination |
IL101144A (en) * | 1991-03-06 | 1996-09-12 | Wellcome Found | Pharmaceutical preparations containing 1 -) 2 -) hydroxymethyl (- 1, 3 - oxathiolan-5 - il (5) fluorescitosin and its derivatives for the treatment of their hepatitis B virus infections |
WO1992018517A1 (en) * | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
GB9110874D0 (en) * | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
ZA923640B (en) * | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
-
1992
- 1992-08-25 US US07/935,515 patent/US5925643A/en not_active Expired - Lifetime
-
1993
- 1993-08-25 JP JP50661694A patent/JP3519736B2/ja not_active Expired - Fee Related
- 1993-08-25 AU AU50933/93A patent/AU670637C/en not_active Withdrawn - After Issue
- 1993-08-25 CA CA002143107A patent/CA2143107C/en not_active Expired - Lifetime
- 1993-08-25 AT AT00203932T patent/ATE498624T1/de not_active IP Right Cessation
- 1993-08-25 AT AT93920366T patent/ATE201599T1/de active
- 1993-08-25 DE DE69330274T patent/DE69330274T2/de not_active Expired - Lifetime
- 1993-08-25 PT PT93920366T patent/PT656778E/pt unknown
- 1993-08-25 DE DE69334348T patent/DE69334348D1/de not_active Expired - Lifetime
- 1993-08-25 ES ES93920366T patent/ES2157929T3/es not_active Expired - Lifetime
- 1993-08-25 EP EP00203932A patent/EP1081148B1/en not_active Expired - Lifetime
- 1993-08-25 DK DK93920366T patent/DK0656778T3/da active
- 1993-08-25 EP EP93920366A patent/EP0656778B1/en not_active Expired - Lifetime
- 1993-08-25 WO PCT/US1993/008044 patent/WO1994004154A1/en active IP Right Grant
-
1995
- 1995-06-06 US US08/469,465 patent/US5767122A/en not_active Expired - Lifetime
-
2001
- 2001-08-14 GR GR20010401249T patent/GR3036393T3/el unknown
- 2001-08-22 JP JP2001251947A patent/JP4503206B2/ja not_active Expired - Fee Related
-
2003
- 2003-12-12 JP JP2003414876A patent/JP2004149543A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DK0656778T3 (da) | 2001-07-30 |
US5925643A (en) | 1999-07-20 |
DE69330274D1 (de) | 2001-07-05 |
DE69334348D1 (de) | 2011-03-31 |
ATE498624T1 (de) | 2011-03-15 |
AU670637C (en) | 2002-07-25 |
WO1994004154A1 (en) | 1994-03-03 |
EP0656778A1 (en) | 1995-06-14 |
JP3519736B2 (ja) | 2004-04-19 |
EP0656778B1 (en) | 2001-05-30 |
EP1081148B1 (en) | 2011-02-16 |
ES2157929T3 (es) | 2001-09-01 |
CA2143107A1 (en) | 1994-03-03 |
EP1081148A3 (en) | 2003-03-05 |
EP1081148A2 (en) | 2001-03-07 |
JP2004149543A (ja) | 2004-05-27 |
US5767122A (en) | 1998-06-16 |
JP4503206B2 (ja) | 2010-07-14 |
PT656778E (pt) | 2001-09-28 |
JP2002114787A (ja) | 2002-04-16 |
ATE201599T1 (de) | 2001-06-15 |
AU5093393A (en) | 1994-03-15 |
JPH08501086A (ja) | 1996-02-06 |
EP0656778A4 (en) | 1995-08-02 |
AU670637B2 (en) | 1996-07-25 |
CA2143107C (en) | 2004-11-23 |
DE69330274T2 (de) | 2001-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3036393T3 (en) | ENANTIOMERICALLY PURE -g(b)-D-DIOXOLANE-NUCLEOSIDES. | |
HK1082684A1 (en) | Use of B-D-dioxolanyl nucleosides in the manufacturing pharmaceuticals | |
AU1787492A (en) | Antiviral combinations containing nucleoside analogs | |
CA2171550A1 (en) | Nucleosides with anti-hepatitis b virus activity | |
KR0156747B1 (en) | Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis-b | |
AU8559891A (en) | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines | |
AU2101492A (en) | Methanoanthracenes having antidopaminergic activity | |
HK1014660A1 (en) | 3'-Azido-2',3'-dideoxy-5- methylcytidine anti-viral composition | |
AU8447991A (en) | Antineoplastic effect potentiator and antineoplastic agent | |
TW222622B (el) | ||
EP0855398A4 (en) | SESQUITERPEN DERIVATIVES WITH ANTIVITAL ACTIVITY | |
HU9203052D0 (en) | Method for treatment of hypertension | |
ZA948908B (en) | Use of 2-amino purine derivatives for the treatment and pro-phylaxis of human herpes virus 7 infection | |
ZA948907B (en) | Use of 2-amino purine derivatives for the treatment and pro-phylaxis of human herpes virus 6 infections | |
IL109227A0 (en) | Leustroducsin h, pharmaceutical composition containing the same, and processes for the preparation thereof |